Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Denosumab Coverage Update | OpenP…
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0027

    Denosumab Agents

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0027 alerts

    Get alerted when Policy CC-0027 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity, prior-authorization, step-therapy, quantity-limit, and coding requirements for Prolia, Xgeva, and listed denosumab biosimilars for osteoporosis, glucocorticoid-induced osteoporosis, treatment-induced bone loss, metabolic bone disease, malignancy-related indications, giant cell tumor of bone, and hypercalcemia of malignancy.

    Policy Summary
    PayerEmpire Bluecross
    PolicyDenosumab Agents
    Policy CodePolicy CC-0027
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewMay 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization or clinical review requests that satisfy the applicable osteoporosis or metabolic bone disease criteria.
    SourceLink
    POLICY UPDATE CHANGES

    The September 1, 2026 revision updated the step-therapy tables.

    Ponlimsi was added to the Prolia biosimilar clinical criteria, step therapy, quantity limits, and applicable unclassified-drug coding.

    Several denosumab biosimilars transitioned from unclassified-drug codes to specific Q-codes effective July 1, 2026.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Primary clinical indication pathways
    60 mg every 6 monthsOsteoporosis quantity limit
    120 mg per 28 daysMetabolic bone disease quantity limit
    2 dosesAdditional first-month doses when applicable
    08/01/2026Commercial preferred-agent effective date

    Coverage Criteria

    Continuation Therapy for Osteoporosis

    Continuation requests for Prolia, Bildyos, Boncresa, Bosaya, Conexxence, Enoby, Jubbonti, Ospomyv, Osvyrti, Ponlimsi, or Stoboclo may be approved when all applicable criteria are met.

    ALL of the following

    • There is a clinically significant response to therapy, including but not limited to confirmation of no new fractures or reduction of fractures, no worsening vertebral fractures, or no clinically significant adverse reaction.
    • If the individual has been on therapy for 24 months or longer, a repeat BMD demonstrates a stable or increased BMD.>= 24 months

      This BMD requirement applies when the individual has received at least 24 months of therapy.

    Prolia, Bildyos, Boncresa, Bosaya, Conexxence, Enoby, Jubbonti, Ospomyv, Osvyrti, Ponlimsi, Stoboclo, Xgeva, Aukelso, Bilprevda, Bomyntra, Jubereq, Osenvelt, Oziltus, Wyost, Xbryk, and Xtrenbo may not be approved when used in combination with another denosumab agent, including but not limited to the denosumab products listed in this policy.

    Coverage may not be approved when the applicable criteria above are not met or when the requested use is not one of the addressed indications.

    Coverage may not be approved for all other indications outside the stated criteria.

    Coding

    Prolia and biosimilars HCPCSHCPCS
    C9399Unclassified drugs or biologicals [when specified as Ponlimsi (denosumab-adet)]
    J0897Injection, denosumab, 1 mg [Prolia]
    J3590Unclassified biologics [when specified as Ponlimsi (denosumab-adet)]
    Q5136Injection, denosumab-bbdz (Jubbonti), biosimilar, 1 mg
    Q5157Injection, denosumab-bmwo (Stoboclo), biosimilar, 1 mg
    Q5158Injection, denosumab-bnht (Conexxence), biosimilar, 1 mg
    Q5159Injection, denosumab-dssb (Ospomyv), biosimilar, 1 mg
    Q5161Injection, denosumab-kyqq (Bosaya), biosimilar, 1 mg
    Q5162Injection, denosumab-nxxp (Bildyos), biosimilar, 1 mg
    Q5166Injection, denosumab-desu (Osvyrti), biosimilar, 1 mg
    1–10 of 12
    1/2
    Prolia and biosimilars HCPCSHCPCSCovered
    C9399Unclassified drugs or biologicals [when specified as Ponlimsi (denosumab-adet)]
    J0897Injection, denosumab, 1 mg [Prolia]
    J3590Unclassified biologics [when specified as Ponlimsi (denosumab-adet)]
    Q5136Injection, denosumab-bbdz (Jubbonti), biosimilar, 1 mg
    Q5157Injection, denosumab-bmwo (Stoboclo), biosimilar, 1 mg
    Q5158Injection, denosumab-bnht (Conexxence), biosimilar, 1 mg
    Q5159Injection, denosumab-dssb (Ospomyv), biosimilar, 1 mg
    Q5161Injection, denosumab-kyqq (Bosaya), biosimilar, 1 mg
    Q5162Injection, denosumab-nxxp (Bildyos), biosimilar, 1 mg
    Q5166Injection, denosumab-desu (Osvyrti), biosimilar, 1 mg
    1–10 of 12
    1/2
    Prolia and biosimilars ICD-10 DiagnosisICD-10Covered
    C50.011-C50.929Malignant neoplasm of breast
    C61Malignant neoplasm of prostate
    M80.00XA-M80.88XSOsteoporosis with current pathological fracture
    M81.0-M81.8Osteoporosis without current pathological fracture
    M85.80-M85.9Other specified disorders of bone density and structure [osteopenia]
    N95.1Menopausal and female climacteric states
    Z08Encounter for follow-up examination after completed treatment for malignant neoplasm
    Z51.11-Z51.12Encounter for antineoplastic chemotherapy and immunotherapy
    Z78.0Postmenopausal status NOS
    Z79.51-Z79.52Long term (current) use of steroids
    1–10 of 14
    1/2
    Xgeva and biosimilars HCPCSHCPCSCovered
    J0897Injection, denosumab, 1 mg [Xgeva]
    Q5136Injection, denosumab-bbdz (Wyost), biosimilar, 1 mg
    Q5157Injection, denosumab-bmwo (Osenvelt), biosimilar, 1 mg
    Q5158Injection, denosumab-bnht (Bomyntra), biosimilar, 1 mg
    Q5159Injection, denosumab-dssb (Xbryk), biosimilar, 1 mg
    Q5161Injection, denosumab-kyqq (Aukelso), biosimilar, 1 mg
    Q5162Injection, denosumab-nxxp (Bilprevda), biosimilar, 1 mg
    Q5165Injection, denosumab-mobz (Oziltus), biosimilar, 1 mg
    Q5166Injection, denosumab-desu (Jubereq), biosimilar, 1 mg
    Q5167Injection, denosumab-qbde (Xtrenbo), biosimilar, 1 mg
    Xgeva and biosimilars ICD-10 DiagnosisICD-10Covered
    C00.0-C76.8Malignant neoplasms
    C79.51Secondary malignant neoplasm of bone
    C90.00-C90.32Multiple myeloma and malignant plasma cell neoplasms
    D48.0Neoplasm of uncertain behavior of bone and articular cartilage [specified as GCTB]
    E83.52Hypercalcemia
    Z08Encounter for follow-up examination after completed treatment for malignant neoplasm
    Z51.11-Z51.12Encounter for antineoplastic chemotherapy and immunotherapy
    Z79.899Other long term (current) drug therapy [prophylactic drug therapy]
    Z85.00-Z85.59Personal history of malignant neoplasms
    Z85.810-Z85.9Personal history of malignant neoplasms
    Osteoporosis BMD threshold
    BMD thresholdT-score less than or equal to -2.5
    Measurement sitesSpine, femoral neck, total hip, or distal one-third of the radius
    Reference populationCompared with a young-adult reference population
    Low body weight risk factor
    Weight thresholdLess than 57.6 kg
    Risk-factor categoryLow body weight is a risk factor for osteoporotic fracture

    Provider Actions

    Prior Authorization

    Medical-Benefit Prior Authorization and Clinical Review

    Requests for denosumab agents subject to the member’s medical benefit or clinical review, including prior authorization, require clinical review against the applicable medical-necessity criteria before approval.

    • Submit the requested product, indication, dosing, and clinical documentation with the medical-benefit prior authorization request.
    • Apply the osteoporosis criteria for Prolia and osteoporosis biosimilars and the metabolic bone disease criteria for Xgeva and metabolic bone disease biosimilars.
    • Approval is contingent on meeting the applicable clinical criteria and any plan-specific requirements.
    Step Therapy

    Check Preferred Denosumab Requirements

    When denosumab is clinically approvable, the benefit plan may require use of a preferred denosumab agent. For osteoporosis and metabolic bone disease, identify the preferred agent before requesting a non-preferred product and document the applicable exception if needed.

    Background

    Denosumab is a subcutaneous, fully human monoclonal antibody that targets RANKL. This policy addresses its use for osteoporosis, including glucocorticoid-induced osteoporosis and treatment-induced bone loss, as well as malignancy-related skeletal complications, hypercalcemia of malignancy, and giant cell tumor of bone. Osteoporosis may be established by a bone mineral density T-score of ≤ -2.5 or by a qualifying low-trauma fracture.

    Definitions

    Osteoporosis
    BMD criterionT-score in the spine, femoral neck, total hip, or distal one-third of the radius of less than or equal to -2.5
    ReferenceCompared with a young-adult reference population
    Alternative clinical diagnosisA history of a fragility fracture may also establish the diagnosis
    Fragility fracture
    DefinitionA fracture resulting from low trauma or minimal trauma
    Clinical terminologyAlso described as a low-trauma fracture
    Policy relevance

    Initial Therapy Criteria

    Osteoporosis Initial Therapy: Prolia and Biosimilars

    The following products may be approved for initial osteoporosis therapy when ONE of the applicable osteoporosis pathways is met: Prolia, Bildyos, Boncresa, Bosaya, Conexxence, Enoby, Jubbonti, Ospomyv, Osvyrti, Ponlimsi, or Stoboclo.

    Osteoporosis eligibility pathways

    • Osteoporosis by BMD

      • Individual is a male or postmenopausal female with osteoporosis defined by a BMD T-score of less than or equal to -2.5 in the spine, femoral neck, total hip, or distal one-third of the radius.BMD T-score <= -2.5
      • ONE of

        • At least one osteoporotic or minimal-trauma fracture.

    Continuation Criteria

    Osteoporosis Continuation: Prolia and Biosimilars

    Continuation requests for Prolia and the listed osteoporosis biosimilars—Bildyos, Boncresa, Bosaya, Conexxence, Enoby, Jubbonti, Ospomyv, Osvyrti, Ponlimsi, and Stoboclo—may be approved when ALL of the following are met:

    Continuation response

    • There is clinically significant response to therapy, including no new fractures or a reduction in fractures, no worsening vertebral fractures, or no clinically significant adverse reaction.

      Response examples are not exhaustive.

    • If the individual has been on therapy for at least 24 months, repeat BMD demonstrates stable or increased BMD.Stable or increased BMD after >= 24 months

    Step Therapy

    StepPreferred therapy requirementException for non-preferred coverage
    1Trial of the preferred denosumab agent for osteoporosis.The individual has an allergy or severe intolerance to an inactive ingredient in the preferred agent that interferes with use, and the same reaction is not expected with the requested non-preferred agent. Convenience factors, such as dosage form, device, concentration, or regimen, do not qualify.
    StepPreferred therapy requirementException for non-preferred coverage
    1Trial of the preferred denosumab agent for metabolic bone disease.The individual has an allergy or severe intolerance to an inactive ingredient in the preferred agent that interferes with use, and the same reaction is not expected with the requested non-preferred agent. Convenience factors, such as dosage form, device, concentration, or regimen, do not qualify.

    Quantity Limits

    Prolia and osteoporosis biosimilars
    ProductsProlia and listed osteoporosis biosimilars: Bildyos, Boncresa, Bosaya, Conexxence, Enoby, Jubbonti, Ospomyv, Osvyrti, Ponlimsi, and Stoboclo
    Dose60 mg
    Quantity limitOne prefilled syringe every 6 months
    Xgeva and metabolic bone disease biosimilars
    ProductsXgeva and listed metabolic bone disease biosimilars: Aukelso, Bilprevda, Bomyntra, Jubereq, Osenvelt, Oziltus, Wyost, Xbryk, and Xtrenbo
    Standard limitOne vial per 28 days
    Bomyntra supply

    Biosimilar Products and Preferences

    Billing Rule

    Prolia biosimilar agents

    The following products are listed as Prolia biosimilar agents for osteoporosis.

    • Bildyos
    • Boncresa
    • Bosaya
    • Conexxence
    • Enoby
    • Jubbonti
    • Ospomyv
    • Osvyrti
    • Ponlimsi
    • Stoboclo
    Billing Rule

    Xgeva biosimilar agents

    Policy Summary
    PayerEmpire Bluecross
    PolicyDenosumab Agents
    Policy CodePolicy CC-0027
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewMay 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization or clinical review requests that satisfy the applicable osteoporosis or metabolic bone disease criteria.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider ActionsBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep TherapyQuantity LimitsBiosimilar Products and Preferences
    Clinical contextUsed among multiple risk factors when assessing higher fracture risk
    Glucocorticoid risk factor
    MedicationGlucocorticoid therapy
    Daily dosePrednisone-equivalent dose of 5 mg or greater
    DurationAt least 3 months
    Glucocorticoid-induced osteoporosis treatment
    MedicationSystemic glucocorticoid therapy
    Daily dosePrednisone-equivalent dose of 7.5 mg or greater
    Expected durationAt least 6 months
    Continuation BMD review
    Review timingAfter at least 24 months of therapy
    Required assessmentRepeat bone mineral density (BMD) measurement
    Acceptable resultBMD must be stable or increased
    Hypercalcemia of malignancy threshold
    Corrected calcium thresholdAlbumin-corrected serum calcium greater than 12.5 mg/dL
    SI-unit equivalentGreater than 3.1 mmol/L
    IndicationTreatment of hypercalcemia of malignancy
    Recent intravenous bisphosphonate treatment
    Treatment typeIntravenous bisphosphonate therapy
    TimingWithin the last 30 days
    Response requirementHypercalcemia of malignancy must be refractory to the recent treatment
    • Preferred-agent lists are available through the plan.
    • The preferred-agent requirement applies separately to denosumab requests for osteoporosis and metabolic bone disease.
    • A non-preferred agent is not approvable solely because it offers greater convenience.
    Documentation Required

    Osteoporosis Clinical Documentation

    For an osteoporosis request, document the applicable diagnosis and clinical basis for treatment. The record must support osteoporosis by BMD or fragility fracture and include relevant fracture-risk factors or prior-therapy history.

    • Document that the individual is a male or postmenopausal female with osteoporosis, generally supported by a BMD T-score of ≤ -2.5 at the spine, femoral neck, total hip, or distal one-third of the radius, or by a history of at least one low-trauma (fragility) fracture.
    • Document at least one osteoporotic/minimal-trauma fracture, or at least two risk factors for osteoporotic fracture, or failure, intolerance, or contraindication to another osteoporosis therapy such as a bisphosphonate.
    • For glucocorticoid-induced osteoporosis, document the qualifying BMD or fragility fracture, current or planned systemic glucocorticoid therapy equivalent to ≥7.5 mg prednisone daily, and expected duration of at least 6 months, plus a qualifying fracture, at least two risk factors, or failure/intolerance/contraindication to another therapy.
    • For postmenopausal patients receiving adjuvant aromatase-inhibitor therapy for breast cancer or males receiving androgen-deprivation therapy for nonmetastatic prostate cancer, document the therapy and the required fracture or additional-risk-factor history.
    Documentation Required

    Document Response for Continuation

    For continuation therapy, document a clinically significant response to denosumab. If treatment has continued for at least 24 months, include repeat BMD results showing stable or increased BMD.

    • Document no new fractures or a reduction in fractures, no worsening vertebral fractures, or no clinically significant adverse reaction, as applicable.
    • For therapy ≥24 months, submit repeat BMD demonstrating stable or increased BMD.
    Documentation Required

    Metabolic Bone Disease Documentation

    For metabolic bone disease requests, document the qualifying diagnosis, age or skeletal maturity, and the clinical details supporting the requested use.

    • For prevention of skeletal-related events, document age ≥18 years and multiple myeloma, bone metastases from a solid tumor other than prostate cancer, or bone metastases from castration-resistant/recurrent prostate cancer.
    • For hypercalcemia of malignancy, document age ≥18 years, albumin-corrected serum calcium >12.5 mg/dL (3.1 mmol/L), and refractoriness to recent intravenous bisphosphonate therapy within the preceding 30 days.
    • For localized or metastatic giant cell tumor of bone, document that the tumor is unresectable or resection would likely cause severe morbidity, and document age ≥18 years or skeletal maturity in an adolescent, such as a closed epiphyseal growth plate of a mature long bone.
    Step Therapy

    Non-Preferred Product Exception

    A non-preferred denosumab agent may be approved only after a trial of the preferred agent and documentation that an inactive ingredient causes an allergy or severe intolerance interfering with use, with no expectation that the same reaction will occur with the requested product.

    • Document the preferred denosumab agent trial and the specific inactive-ingredient allergy or severe intolerance.
    • Explain how the reaction interferes with use of the preferred agent and why it is not expected with the non-preferred agent.
    • The exception pathway applies to both osteoporosis and metabolic bone disease requests.
    Denial Risk

    Denial Risks: Duplicate Therapy or Unmet Criteria

    Denosumab is not approvable when it is being used in combination with another denosumab agent or when the applicable clinical criteria are not met. Requests for all other indications are also subject to denial.

    • Do not request concurrent therapy with another denosumab product, including products from the osteoporosis or metabolic bone disease lists.
    • Confirm that the requested indication and all applicable age, diagnosis, treatment-history, and response requirements are supported before submission.
    Denial Risk

    Convenience-Only Requests May Be Denied

    A request for a non-preferred denosumab agent may not be approved when the rationale is convenience alone. Convenience of dosage form or device, dosage concentration, or regimen does not satisfy the exception pathway.

    • A preferred-agent trial and qualifying inactive-ingredient allergy or severe intolerance are still required.
    • Do not rely solely on a preferred product’s administration format, concentration, device, or dosing schedule to support an exception.
    Billing Rule

    Quantity Limits and First-Month Exceptions

    Quantity limits apply by indication and product. Submit an exception request when the prescribed quantity exceeds the standard limit and document the clinical reason for the additional doses.

    • Osteoporosis denosumab products are generally limited to 60 mg (one prefilled syringe) every 6 months.
    • Metabolic bone disease denosumab products are generally limited to one 120 mg vial or prefilled syringe per 28 days.
    • During the first month of therapy, up to two additional 120 mg doses may be approved for giant cell tumor of bone or hypercalcemia of malignancy.
    May support a clinical diagnosis of osteoporosis
    Failure or refractory disease
    BMD criterionA decline in bone mineral density of at least 5% while on therapy
    Fracture criterionA fragility fracture while on therapy
    Related termFailure of other osteoporosis therapy is also referred to as refractory disease
    Giant cell tumor of the bone
    Tumor typeGiant cell tumor of the bone
    Disease extentLocalized or metastatic
    Surgical statusUnresectable or likely to cause severe morbidity if surgically resected
    Hypercalcemia of malignancy
    Corrected calciumAlbumin-corrected serum calcium greater than 12.5 mg/dL
    Equivalent measurementGreater than 3.1 mmol/L
    Associated conditionMalignancy-related hypercalcemia
    Skeletally mature adolescent
    PopulationAdolescent
    Skeletal maturityAt least one mature long bone
    ExampleA closed epiphyseal growth plate of the humerus
    Two or more risk factors for osteoporotic fracture.
  1. Failure, intolerance, or medical contraindication to another available osteoporosis therapy, such as a bisphosphonate.
  2. Osteoporosis by fragility fracture

    • Individual is a male or postmenopausal female with osteoporosis based on a history of at least one low-trauma fracture (fragility fracture).
  3. Glucocorticoid-induced osteoporosis

    • Glucocorticoid-induced osteoporosis is established by a BMD T-score of less than or equal to -2.5 or a clinical diagnosis based on a low-trauma fracture.BMD T-score <= -2.5 or qualifying low-trauma fracture
    • Individual is initiating or continuing systemic glucocorticoids at a prednisone-equivalent dose of at least 7.5 mg daily, expected for at least 6 months.Prednisone-equivalent dose >= 7.5 mg daily for at least 6 months
    • ONE of

      • At least one osteoporotic or minimal-trauma fracture.
      • Two or more risk factors for osteoporotic fracture.
      • Failure, intolerance, or medical contraindication to another available osteoporosis therapy.
  4. Adjuvant aromatase inhibitor therapy

    • Individual is a postmenopausal, natural or induced, female receiving adjuvant aromatase inhibitor therapy for breast cancer.
    • Individual has had at least one osteoporotic or minimal-trauma fracture.
  5. Androgen-deprivation therapy

    • Individual is a male receiving androgen-deprivation therapy for non-metastatic prostate cancer.
    • ONE of

      • At least one osteoporotic or minimal-trauma fracture.
      • One or more additional risk factors for osteoporotic fracture.
  6. 120 mg in one vial or one prefilled syringe
    Additional first-month doses
    Eligible indicationsGiant cell tumor of the bone or hypercalcemia of malignancy
    Additional quantityTwo additional 120 mg doses
    TimingMay be approved during the first month of therapy

    The following products are listed as Xgeva biosimilar agents for metabolic bone disease.

    • Aukelso
    • Bilprevda
    • Bomyntra
    • Jubereq
    • Osenvelt
    • Oziltus
    • Wyost
    • Xbryk
    • Xtrenbo
    Billing Rule

    Commercial benefit: Prolia preference

    For the commercial medical benefit, Prolia is the preferred agent effective August 1, 2026. The listed Prolia biosimilars are non-preferred agents.

    • Preferred: Prolia.
    • Non-preferred: Bildyos, Boncresa, Bosaya, Conexxence, Enoby, Jubbonti, Ospomyv, Osvyrti, Ponlimsi, Stoboclo.
    • Effective date: 08/01/2026.
    Billing Rule

    Commercial benefit: Xgeva preference

    For the commercial medical benefit, Xgeva is the preferred agent effective August 1, 2026. The listed Xgeva biosimilars are non-preferred agents.

    • Preferred: Xgeva.
    • Non-preferred: Aukelso, Bilprevda, Bomyntra, Jubereq, Osenvelt, Oziltus, Wyost, Xbryk, Xtrenbo.
    • Effective date: 08/01/2026.
    Billing Rule

    Medicare benefit: Prolia preference

    For the Medicare medical benefit, Prolia is preferred effective July 1, 2026. The listed Prolia biosimilars are non-preferred agents.

    • Preferred: Prolia.
    • Non-preferred: Bildyos, Boncresa, Bosaya, Conexxence, Enoby, Jubbonti, Ospomyv, Osvyrti, Stoboclo.
    • Effective date: 07/01/2026.
    Billing Rule

    Medicare benefit: Xgeva preference

    For the Medicare medical benefit, Xgeva is preferred effective July 1, 2026. The listed Xgeva biosimilars are non-preferred agents.

    • Preferred: Xgeva.
    • Non-preferred: Ponlimsi, Stoboclo, Aukelso, Bilprevda, Bomyntra, Jubereq, Osenvelt, Oziltus, Wyost, Xbryk.
    • Effective date: 07/01/2026.